STAT First Opinion: Right-to-Try Legislation Offers False Hope and Would Endanger Patients

In an invited commentary, Dr. Michael Carome, director of Public Citizen’s Health Research Group, explains why so-called “right-to-try” legislation that was passed by the U.S. Senate and is now being considered by the U.S. House of Representatives would create a dangerous, uncharted pathway for patients to access experimental medications. The legislation would effectively undermine the FDA’s safety rules regarding the use of experimental drugs outside the context of a clinical trial, putting countless patients at risk.

View the full STAT publication here.